The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...